Why ImmuCell Corporation’s (ICCC) Stock Is Down 5.52%
As of Tuesday, November 17, ImmuCell Corporation’s ICCC share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Omar Beirat
Rosalio Madrigal
| Share Statistics | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $102.9 | $208.2 | 23% |
|
| Shares Out (Mil) | 9.3 | 55.4 | 20% |
|
| Institutional Ownership | 42.8% | 92.9% | 18% |
|
| Float (Mil) | 6.0 | 40.7 | 14% |
|
| Beta | na | 1.00 | na |
|
| Avg Daily Volume (000s) | 21 | 570 | 22% |
|
| Price Change (52-week) |
109.8% | 40.7% | 96% |
|
| Growth | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.5% | 13.2% | 67% |
|
| Net Income (5yr) | 0.0% | (10.3%) | 40% |
|
| EPS (5yr) | 3.3% | 15.5% | 36 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.6%) | (15.7%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $33 | $39 | 17% |
|
| Net Income (TTM) (Mil) | $2 | ($44) | 40% |
|
| EPS (TTM) | $0.207 | ($1.400) | 46% |
|
| Operating Cash Flow (TTM) (Mil) | $8 | ($34) | 37% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $-0 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $97 | $138 | 22% |
|
| Valuation | ICCC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.14 | 1.96 | 70% |
|
| P/E | 57.5 | 17.7 | 89% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 17.4 | 0.8 | 97% |
|
| Ratios | ICCC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 40.8% | 67.9% | 51% |
|
| Net Margin | 5.7% | (50.8%) | 49% |
|
| ROA | 4.0% | (47.4%) | 66% |
|
| ROE | 6.0% | (51.6%) | 45% |
|
| Liabilities to Assets | 31.7% | 29.7% | 23% |
|
| F-Score | 6 | 3 | 67% |
|
ImmuCell Corporation did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors